Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma

esmo - Findings from the ZSAB-neoGOLP study

AI Summary: The ZSAB‑neoGOLP trial shows that giving a four‑drug neoadjuvant regimen—gemcitabine, oxaliplatin, lenvatinib and toripalimab—before surgery prolongs event‑free survival for patients with resectable, high‑risk intrahepatic cholangiocarcinoma. The finding suggests preoperative systemic therapy can downstage aggressive tumors and delay recurrence, potentially changing treatment sequencing for this challenging disease.

NRG-LU005 Trial: Atezolizumab Plus Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer

oncodaily - A major international clinical trial, NRG-LU005, has provided important new insight into how immunotherapy should be used in limited-stage small cell lung cancer (SCLC). While immune checkpoint inhibitors have significantly […]

AI Summary: A major international trial tested whether adding the PD‑L1 inhibitor atezolizumab to concurrent chemoradiotherapy for limited‑stage small‑cell lung cancer would boost outcomes. The study found no significant survival benefit, prompting clinicians to rethink the timing and role of immune checkpoint blockade in curative‑intent SCLC rather than assuming more drugs always means better results.